GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Morepen Laboratories Ltd (NSE:MOREPENLAB) » Definitions » 5-Year EBITDA Growth Rate

Morepen Laboratories (NSE:MOREPENLAB) 5-Year EBITDA Growth Rate : 11.60% (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Morepen Laboratories 5-Year EBITDA Growth Rate?

Morepen Laboratories's EBITDA per Share for the three months ended in Dec. 2024 was ₹0.76.

During the past 12 months, Morepen Laboratories's average EBITDA Per Share Growth Rate was 37.40% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 5.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 11.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Morepen Laboratories was 98.40% per year. The lowest was -32.00% per year. And the median was 8.95% per year.


Competitive Comparison of Morepen Laboratories's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morepen Laboratories's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Morepen Laboratories's 5-Year EBITDA Growth Rate falls into.


;
;

Morepen Laboratories 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Morepen Laboratories  (NSE:MOREPENLAB) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Morepen Laboratories 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Morepen Laboratories's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Morepen Laboratories Business Description

Traded in Other Exchanges
Address
Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.

Morepen Laboratories Headlines

No Headlines